Insider Trading March 18, 2026

RadNet Strategy Chief Disposes Nearly $1 Million in Shares Amid Strong Quarterly Results

Alma Gregory Sorensen reduces stake through two March transactions; company posts Q4 2025 beat and garners bullish analyst targets

By Leila Farooq RDNT
RadNet Strategy Chief Disposes Nearly $1 Million in Shares Amid Strong Quarterly Results
RDNT

Alma Gregory Sorensen, Chief Strategy Officer of RadNet, Inc. (RDNT), sold a total of 15,000 shares of company stock on March 18, 2026, generating about $932,280 in proceeds across two trades. The company also reported stronger-than-expected fourth-quarter 2025 results and continues to receive optimistic analyst price targets and a reiterated Buy rating from Jefferies.

Key Points

  • RadNet CSO Alma Gregory Sorensen sold 15,000 shares on March 18, 2026, for approximately $932,280 across two transactions.
  • On March 16, Sorensen sold an additional 5,919 shares valued at $365,320; she now directly owns 1,223,923 shares.
  • RadNet reported Q4 2025 EPS of $0.23 and revenue of $547.7 million, both beating expectations; Jefferies reaffirmed a Buy rating with a $91 price target and analysts see price targets between $86 and $100.

Alma Gregory Sorensen, RadNet, Inc.'s Chief Strategy Officer, executed the sale of 15,000 shares of common stock on March 18, 2026, cumulatively valued at approximately $932,280. The disposition was carried out in two separate trades recorded the same day.

In the larger of the two transactions Sorensen sold 14,200 shares at an average price of $62.12 per share, with the individual trade prices spanning from $61.65 to $62.65. The smaller transaction comprised 800 shares sold at an average of $62.72, with transactional prices ranging from $62.67 to $63.67.

Two days earlier, on March 16, Sorensen also sold 5,919 shares of RadNet common stock at a price of $61.72 per share, an amount valued at $365,320. Following the March 16 and March 18 transactions combined, Sorensen directly holds 1,223,923 shares of RadNet.

RadNet's shares are trading near the levels recorded in these sales; the stock is quoted at $62.02, close to the average prices reported in the March trades. Separately, InvestingPro analysis referenced in company commentary suggests the stock may be overvalued at current price levels.

On a company-wide basis, RadNet carries a market capitalization of $4.8 billion and reported revenue growth of 11.5%. Analysts covering the company project RadNet will return to profitability in the current year with forecasted earnings of $0.69 per share, following a loss reported over the last twelve months.

Investor sentiment on Wall Street remains positive, with analyst price targets spanning $86 to $100 per share, implying material upside from current prices. Those projections sit alongside the company’s recently reported fourth-quarter 2025 financials, which showed an earnings per share result of $0.23, a beat of analysts’ expectations by 14.03%. Revenue for the quarter totaled $547.7 million, outperforming consensus estimates by 6.03%.

Jefferies has reiterated a Buy rating on RadNet and maintained a price target of $91.00. In its commentary, Jefferies noted that RadNet’s guidance for fiscal 2026 is in line with market expectations and emphasized continued strength in the outpatient imaging segment. The firm also highlighted the company’s ability to sustain double-digit EBITDA growth despite recent operational challenges.


The transactions by the company’s Chief Strategy Officer, coupled with RadNet’s recent quarter that exceeded expectations and positive analyst coverage, provide investors multiple data points to weigh when assessing the stock near its current trading levels.

Risks

  • Insider sales may prompt investor questions about management selling activity relative to company ownership levels - this could affect short-term investor sentiment in the healthcare and financial markets.
  • InvestingPro analysis indicates the stock could be overvalued at current prices, introducing valuation risk for equity investors.
  • Although analysts forecast profitability this year, RadNet posted a loss over the last twelve months, which presents execution and earnings consistency risk for the healthcare services sector.

More from Insider Trading

Penumbra Director Executes $32,822 Stock Sale Amid Deal and Upbeat Quarterly Results Apr 6, 2026 Power Integrations VP Sells 313 Shares to Cover Tax Bill; Stock Up 45% YTD Apr 6, 2026 Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News Apr 6, 2026 Kinder Morgan Vice President Disposes of $203K in Class P Shares Apr 6, 2026 RA Capital Disposes $14.5M of Vor Biopharma Stock Across Early April Trades Apr 6, 2026